

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
19 June 2003 (19.06.2003)

PCT

(10) International Publication Number  
WO 03/049619 A2

(51) International Patent Classification<sup>7</sup>: A61B 17/00,  
17/34, 17/064

(21) International Application Number: PCT/US02/39087

(22) International Filing Date: 6 December 2002 (06.12.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/340,062	8 December 2001 (08.12.2001)	US
60/365,918	20 March 2002 (20.03.2002)	US
60/369,988	4 April 2002 (04.04.2002)	US
10/295,390	15 November 2002 (15.11.2002)	US

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KB, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:


— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(71) Applicant and  
(72) Inventor: LATTOUF, Omar, M. [US/US]; 2419 Highland Grove NE, Atlanta, GA 30345 (US).

(74) Agent: LYNCH, Edward, J.; 600 Beach Street, 3rd Floor, San Francisco, CA 94109 (US).

(54) Title: TREATMENTS FOR A PATIENT WITH CONGESTIVE HEART FAILURE



(57) Abstract: The invention is directed to two minimally invasive therapeutic procedures, particularly for patients with congestive heart failure, and devices and systems for such procedures. One procedure involves providing a valved passageway through the patient's left ventricular wall at the apex of the patient's heart and advancing instruments through the valved passageway to connect the valve leaflets of the patient's heart valve, e.g. the mitral valve, in a "Bow-Tie" configuration to prevent or minimize regurgitation through the valve. The second procedure involves advancing a pacing lead and a pacing lead implanting device through a trocar in the patient's chest and implanting the pacing lead on an exposed epicardial region of the patient's heart wall. The pacing lead has a penetrating electrode which is secured within the heart wall. One or both procedures may be performed on a patient with CHF. Improved devices for these procedures include a minimally invasive grasping device having an inner lumen for advancing connecting members and other instruments through the device to the distal end thereof. Other improved devices include a pacing lead implant instrument which is releasably secured by its distal end to the exposed heart wall to facilitate penetration of the pacing lead electrode into the heart wall. Other improved instruments include a leaflet connector with an artificial cordae tendinae strand secured to an end of the leaflet connector.

WO 03/049619 A2

**TREATMENTS FOR A PATIENT WITH CONGESTIVE HEART FAILURE****CROSS-REFERENCE TO RELATED APPLICATIONS**

This application is a continuation-in-part of application Serial No. 10/295,390, filed on November 15, 2002 which is related to and claims the priority of Provisional Application No. 60/340,062, filed December 8, 2001, Provisional Application Serial No. 60/365,918, filed March 20, 2002, and Provisional Application Serial No. 60/369,988, filed April 4, 2002. The entire contents of these applications are incorporated herein by reference

**BACKGROUND OF THE INVENTION**

This invention is directed to therapeutic procedures for a patient's heart and to instruments and systems for such procedures. The invention is particularly suitable for treating a patient suffering from the symptoms of congestive heart failure (CHF), and particularly to those CHF patients exhibiting mitral valve regurgitation (MVR) and/or those exhibiting intraventricular conduction delay with resulting disturbance of the synchronous right and/or left ventricular contractility.

There are over five million patients in the United States suffering from CHF and there are more than seven hundred thousand new cases of CHF each year. For many of these patients medical therapy is not very successful. Recent trials have shown that a significant number of CHF patient's benefit from percutaneous ventricular pacing where pacing leads are introduced percutaneously and advanced within the patient's vasculature until the leads are disposed within the patient's coronary sinus. However, ventricular pacing has not been found successful for a significant number of CHF patients for a variety of reasons. For example, in a number of procedures the coronary sinus cannot be cannulated due to dilated cardiomyopathy (the deformity of the heart which accompanies CHF) and, even if the coronary sinus is cannulated, the pacing leads can become displaced rendering them ineffective.

With many CHF patients, their ventricular ejection fraction is reduced due to mitral valve regurgitation (MR) which may also result from dilated cardiomyopathy. The MR in turn can exacerbate the cardiomyopathy leading to a worsening of the MR. The MR can also be the result of torn cordae tendinae which extend from the valve leaflets to the papillary muscles, preventing complete closure of the valve.

Surgical procedures for mitral valve repair for MR typically involves valve support ring at the base of valve. Recent advances in mitral valve repair include securing together the free edges of the mitral valve leaflets by sutures, staples and the like, commonly called "Bow-Tie" or "edge to edge" techniques. These procedures usually involve open heart surgery, including

cardiopulmonary bypass and a sternotomy, although more recently suggestions have been made of performing these procedures with minimally invasive and percutaneous techniques which can reduce the morbidity of such procedures. Percutaneous procedures impose difficulties in instrument design because the instruments for such procedures must be long enough to extend from the entry location on the patient's leg to the interior of the patient's heart chamber, and they must have small enough profile and have sufficient flexibility for advancement through the patient's vasculature into the patient's heart chamber. Additionally, the instruments for such percutaneous procedures must also be able to accurately locate the operative distal ends of such instruments at a desired location within the chambers of the patient's beating heart and be strong enough to perform the required functions.

Techniques for Bow-Tie repair of mitral valves have been mentioned in the patent literature, but specific instruments for such techniques are not yet commercially available.

### **SUMMARY OF THE INVENTION**

This invention generally relates to minimally invasive therapeutic procedures, including valve repair and ventricular pacing, for patients with CHF and to the devices and systems suitable for use in such procedures. Specifically, one feature of the invention is directed to gaining access to the patient's heart valve, preferably from within the heart chamber. Such access may be gained through the wall of the patient's heart, such as at the apex thereof, for repairing damaged or otherwise incompetent heart valves. The invention is also directed to the attachment of a pacing lead to an exterior region of the patient's heart wall for ventricular pacing. These procedures provided alone and particularly when performed together provide significant relief and longer life to symptomatic CHF patients. Moreover, due to the minimally invasive nature of these procedures, many of the CHF patient population, who are otherwise unsuitable for conventional surgical treatments, may be treated with the present procedures. As used herein the expression "minimally invasive" refers to procedures in which one or more small openings are made in a patient's chest wall to insert the instruments to be used in performing or observing the procedure. Typically, such procedures utilize trocars within the small chest wall openings having inner lumens with transverse dimensions not greater than 20 mm, preferably about 5 to about 15 mm.

The procedure related to valve repair generally includes first gaining access to the patient's chest cavity through a small opening made in the patient's chest, preferably though an intercostal space between two of the patient's ribs. Such accessing can be effected thoroscopically through an intercostal space between the patient's ribs by minimally invasive

procedures wherein a trocar or other suitable device is placed within the small opening made in the patient's chest.

To the extent required, the patient's deflated lung is moved out of the way, and then the pericardium on the patient's heart wall is removed to expose a region of the epicardium. The patient's heart wall is pierced at the exposed epicardial location to provide a passageway through the heart wall to a heart cavity such as the left ventricle, defined in part by the pierced heart wall. Preferably, the passageway is formed through a region of the heart wall at or near the apex of the patient's heart. Suitable piercing elements include a 14 gauge needle. A guide wire is advanced through the inner lumen of the needle into the heart chamber and further advanced through the valve to be treated, e.g. the mitral valve, into an adjacent heart chamber. The penetrating needle may then be removed leaving the guide wire in place. A valve for the ventricular wall is advanced over the guide wire and installed in the ventricular wall passageway formed by the needle. The valve is configured to enable passage of instruments for the procedure through the heart wall into the heart chamber while preventing loss of blood through the passageway. The valve may be disposed permanently or temporarily within the heart wall passageway.

The valve has a cylindrical body with a valve element disposed within an inner lumen of the cylindrical body. At least the distal end and preferably both ends of the valve are provided with securing elements such as hooks or barbs to fix or otherwise secure the valve within the heart wall passageway. An inflatable dog-boned shape balloon may be utilized to seat the securing elements of the valve within the passageway. Suitable other means for securing valve in the ventricular wall include adhesives, sutures, clip and the like. The valve element within the inner lumen of the valve may take a variety of forms, but a duck-billed valve oriented toward the heart chamber is presently preferred.

The instruments for performing the procedure may be passed through the valve seated in the ventricular passageway. The proximal ends of these instruments extend out of the patient to allow the instruments to be manually or robotically manipulated to accurately position the operative ends of the instruments at the desired location within the heart chamber to perform the procedure and to operate the operative member which may be provided on the distal ends of these instruments from outside the patient's body.

For "Bow-Tie" valve repair on a beating heart, the valve leaflets should be stabilized to facilitate grasping the leaflets with a suitable grasping device at a grasping location and then securing the free edges of the valve leaflets together by suitable connecting members such as one or more sutures, clips or staples or adhesive to form the "Bow-Tie" connection. A suitable stabilizing instrument, particularly for mitral or atrioventricular valve repair, is an elongated catheter having one or more expandable members on a distal location thereof, such as an

inflatable balloon or expandable arms, which can engage the atrial surface of the valve leaflets to stabilize and urge the valve leaflets toward the grasping location. The grasping member grasps and holds the valve leaflets together so that the free edges of the leaflets can be secured together by suitable connecting member or element. The elongated stabilizing instrument is advanced through the ventricular wall valve, through the heart chamber defined in part by the ventricular wall until the distal extremity of the instrument having the expandable member(s) is advanced through the heart valve into the heart chamber beyond the heart valve, which in this case is the left atrium. The expandable member(s) e.g. an inflatable balloon or one or more arms are expanded and then the stabilizing instrument is pulled proximally so the expandable member(s) engage the atrial side of the valve leaflets and move the valve leaflets into the grasping location within the ventricular chamber, e.g. left ventricle.

An elongated grasping device with at least a pair of grasping members such as jaws on the distal end thereof for grasping tissue structure is advanced through the ventricular wall valve until the distal end of the device extends into the heart chamber. The grasping members or jaws of the grasping device are operated from the proximal end of the grasping device which extends out of the patient's chest. The jaws of the grasping device are opened to receive the stabilized valve leaflets in the grasping location and then closed to grip the leaflets so that the free edges of the valve leaflets are placed into an operative position for the "Bow-Tie" repair. The free edges of the grasped valve leaflets may be joined or otherwise secured together by suitable connecting elements. Once the free edges of the valve leaflets are secured together, the instruments for the procedure may be withdrawn through the ventricular wall valve and then the opening in the patient's chest. The ventricular wall valve will close upon instrument removal to eliminate or at least minimize blood leakage through the valve. The ventricular wall valve may be left in place or the valve may be removed and the passageway sutured or otherwise suitably closed.

When there is cordae tendinae damage with the heart valve, particularly when there is severance of the cordae tendinae from the valve leaflet or the papillary muscle, repair of the valve leaflet, even by means of the "Bow-Tie" technique, may not prevent reshaping of the ventricular architecture which can reduce ventricular output.

In that instance, it has been found that providing an artificial cordae tendinae such as a strand with one end secured to the secured valve leaflets and another end secured to the heart wall, particularly in the same orientation as the natural cordae tendinae, will support the connected valve leaflets in more or less a normal manner to minimize ventricular deformation (e.g. dilated cardiomyopathy) which leads to decreased output. One end of the strand is secured to the connecting element securing the free edges of the valve leaflets or to the connected free edges themselves and the other end of the strand is secured to a location on the heart wall,

preferably on the exterior of the heart wall passing through the ventricular wall valve or if the valve is removed through the ventricular wall passageway. The strand should be relatively inelastic or non-compliant to ensure an effective closed position of the leaflets. A suitable strand material is polytetrafluoroethylene (PTFE). In this case it is preferred that the passageway through the ventricular wall pass through the apex region of the heart between the two papillary muscles in the left ventricle, so that the pull on the valve leaflets by the strand secured to the leaflets is in approximately the same angle or orientation as the natural pull by the competent cordae tendinae. This provides for a better seal of the leaflets and thereby minimizes leakage through the valve. The "Bow-Tie" procedure in conjunction with the use of an artificial cordae tendinae extending between the secured valve leaflets and the heart wall may be used with mini-thoracotomy procedures and open chest procedures, both on and off pump, in addition to the minimally invasive procedures described herein.

While the procedure directed to accessing a patient's heart chamber is primarily described herein for repairing damaged or otherwise incompetent valves between chambers of the patient's heart, the procedure and the instruments for such procedures can be employed in a variety of treatments or diagnoses within the patient's heart chambers. Other procedures which may be performed include transmyocardial revascularization (TMR), aortic stenting for aortic dissections and aneurysm therapy, removal of clots and vegetations of prosthetic valves, excision of heart tumors, stem cell and vascular growth factor implantation, ventricular septal defect closure and the like. In TMR procedures a tissue ablation instrument is advanced into the heart chamber to ablate tissue in an ischemic region of the ventricular wall. It is generally thought that the tissue ablation in the ischemic region causes or results in angiogenesis and thus revascularization which returns blood flow to the ischemic region. For TMR procedures in some regions of the heart chamber, a guiding catheter having a preshaped distal tip may be needed to orient the ablating tip to the desired ischemic region of the patient's heart wall. A similar procedure may be utilized to ablate regions of the intraventricular wall to terminate or curtail arrhythmia. Other procedures are contemplated.

The minimally invasive procedure for placement of a pacing lead having a penetrating electrode is performed through a small opening in the patient's chest formed in the intercostal space between the patient's ribs. The small opening is preferably provided with a suitable trocar such as those available commercially. The pericardium is removed from the desired region of the patient's heart to expose the underlying epicardium. The distal end of the pacing lead is introduced into the patient's chest cavity through the trocar seated in the small opening in the patient's chest and the penetrating electrode on the distal end of the pacing lead is inserted into the ventricular wall through the exposed epicardial surface. The proximal end of the pacing lead

s configured to be connected to an electrical power source such as those power sources used for pacing purposes. Such power sources produce a pulsed electrical output of suitable frequency, current and voltage levels to control the contraction of the ventricular wall to which the pacing lead is attached. The proximal end of the pacing lead may be tunneled subcutaneously to the power source which is preferably located in the infraclavical pocket. The penetrating electrode preferably has one or more hooks or other suitable structure for preventing or minimizing the chances for removal of the electrode from the heart wall. The penetrating electrode on the distal end of the pacing lead may take the form of an arrow, fish-hook or helical coil. Other shapes are suitable.

The devices suitable for installing the pacing lead in the exterior of the heart wall are configured to be advanced through the trocar or small opening in the patient's chest and to press or otherwise put the penetrating electrode of the pacing lead within the ventricular wall. The device has a vacuum or other suitable system such as releasable hooks or grasping components on the distal end thereof to secure the distal end of the device to the exposed surface of the epicardium in order to facilitate the placement of the penetrating electrode. The pacing lead and the delivery device are operatively connected with a force applying member that applies the force to the distal portion of the pacing lead required for the electrode to penetrate the ventricular wall. Once the electrode is properly secured within the ventricular wall, the electrical pulses emitted from the pacing electrode override the natural pulses to control the contraction of the heart wall.

The blood flow output from the CHF patient's heart due to the pacing and valve repair in accordance with the present invention is greatly increased, and leads to significant improvement in the physical well being, the life extension and the quality of life of the CHF patient.

These and other advantages of the invention will become more apparent from the following detailed description and accompanying exemplary drawings.

#### **BRIEF DESCRIPTION OF THE DRAWINGS**

Fig. 1 is a perspective view of a patient's chest, partially illustrating the location of the patient's heart within the chest cavity, with part of the heart wall removed to expose the left ventricular chamber and to illustrate torn cordae tendinae connected to one of the valve leaflets.

Fig. 2A is a transverse cross-sectional view taken along the lines 2-2 shown in Fig. 1 illustrating the incompetent mitral valve in a closed condition during systole.

Fig. 2B is a transverse cross-sectional view taken along the lines 2-2 shown in Fig. 1 illustrating the incompetent valve in an open condition during diastole.

Figs 3A and 3B are transverse cross-sectional views similar to those shown in Figs. 2A and 2B but illustrating a competent mitral valve.

Figs. 4A and 4B are transverse cross-sectional views similar to those shown in Figs. 2A and 2B wherein the valve leaflets are secured together in a "Bow-Tie" configuration.

Fig. 5 is a partial elevational view in section of a patient's left ventricle and left atrium illustrating a ventricular wall valve seated in the apical ventricular wall.

Fig. 6 is an enlarged perspective view of the ventricular wall valve shown in Fig. 5.

Fig. 7 is an enlarged elevational view in section taken along the lines 7-7 shown in Fig. 6.

Fig. 8 is a top view of the valve taken along the lines 8-8 shown in Fig. 6.

Fig. 9 is a partial elevational view, in section of the left side of the patient's heart illustrating the positioning of a guide wire in the patient's heart interior with the shaped distal tip of a guide wire in the patient's left atrium.

Fig. 10 is a partial elevational view, in section of the left side of the patient's heart illustrating the advancement of a grasping device over the guide wire shown in Fig. 9.

Fig. 11 is a partial elevational view, in section of the left side of the patient's heart illustrating the positioning of the grasping members on the distal end of the grasping device shown in Fig. 10 over the guide wire into the patient's left atrium.

Fig. 12 is a partial elevational view, in section of the left side of the patient's heart illustrating the advancement of a balloon catheter into an inner lumen of the grasping device for deployment within the patient's left atrium.

Fig. 13 is a partial elevational view, in section of the left side of a patient's heart illustrating the inflation of the balloon on the distal end of the balloon catheter within the patient's left atrium.

Fig. 14 is a partial elevational view, in section of the left side of a patient's heart illustrating the positioning of the valve leaflets in a grasping location by the balloon catheter with the open grasping members of the grasping device being disposed within the left ventricle in a position to grasp the valve leaflets.

Fig. 15 is a partial elevational view, in section of the left side of a patient's heart illustrating the grasping of the valve leaflets by the grasping members of the grasping device.

Fig. 16 is a partial elevational view, in section of the left side of a patient's heart illustrating the connecting the free edges of the valve leaflets with a clip in a Bow-Tie arrangement.

Fig. 17 is an enlarged view of the distal end of the grasping device as shown in Fig. 16 with a clip is position partially pressed into a connecting relationship with the free edges of the valve leaflets.



Fig. 18 is a transverse cross-sectional view taken along the lines 18-18 shown in Fig. 17 illustrating the clip partially connected to the valve leaflets.

Fig. 19 is an elevational view of a grasping device embodying features of the invention.

Fig. 20 is a transverse cross-sectional view of the grasping device shown in Fig. 19 taken along the lines 20-20.

Fig. 21 is an enlarged longitudinal cross-sectional view of the distal end of the grasping device with a valve leaflet connecting clip slidably disposed within the inner lumen of the grasping device.

Figs. 22-24 are transverse cross-sectional views taken along the lines 22-22, 23-23 and 24-24 respectively of the grasping device shown in Fig. 21.

Fig. 25 is a transverse cross-sectional view taken along the lines 25-25 of the grasping device shown in Fig. 21 illustrating the pusher bar pushing the leaflet connecting clip along the guide way lumen of the grasping device.

Fig. 26A is an enlarged elevational view of the clip with an artificial cordae tendinae strand secured to the closed end of the clip. Claim 26B is an alternative clip construction which has an eyelet for securing the end of the artificial cordae tendinae.

Fig. 27 is a partial elevational view, in section of the left side of a patient's heart illustrating the artificial cordae tendinae extending from the clip to the exterior of the patient's heart.

Fig. 28 is a perspective view of a patient's chest, illustrating the location of the patient's heart within the chest cavity, with part of the heart wall removed to expose the left ventricular chamber and illustrating placement of the penetrating electrode of a pacing lead within the heart wall defining in part the left ventricle.

Figs. 29-31 illustrate a suitable minimally invasive device for implanting a pacing lead in a patient's heart wall.

Fig. 32 illustrates typical locations for trocars in a patient's chest for performing procedures described herein.

Fig. 33 and 34 illustrate an alternative embodiment of a minimally invasive device for implanting a pacing lead in a patient's heart wall.

Fig. 35 is a partial elevational view of an alternative penetrating electrode construction.

Fig. 36 illustrates another minimally invasive device for implanting a pacing lead in a patient's heart wall.

Figs. 37 and 38 illustrate the grasping of the pacing lead by the minimally invasive device shown in Fig. 35 and the rotation thereof to implant the electrode in the ventricular wall of a patient.

The drawings are schematic presentations and not necessarily to scale.

### **DETAILED DESCRIPTION OF EMBODIMENTS OF THE INVENTION**

Fig. 1 illustrates a patient's heart 10 with the left side of the heart in partial cross-section schematically showing the patient's left atrium 11 and left ventricle 12 with a mitral valve 13 disposed between the left atrium and the left ventricle having a posterior valve leaflet 14 and an anterior leaflet 15. Each of the valve leaflets 14 and 15 have cordae tendinae 16 and 17 respectively which are connected to the leaflets and to papillary muscles 18 and 19 respectively within the left ventricle at the apex 20 of the heart. The posterior leaflet 14 of the mitral valve 13 is shown with its cordae tendinae 16 partially torn. The free edge 21 of the posterior leaflet 14 is uncontrolled due to the torn cordae tendinae 16 which makes the valve incompetent to close completely when the heart contracts during systole. The incompletely closed mitral valve 13 results in regurgitation of blood back through the valve into the atrium 11 during systole which in turn results in lowered blood output for the left ventricle 12. The anterior valve leaflet 15 is shown with its cordae tendinae 17 completely attached.

Figs. 2A and 2B illustrate the closed and open condition respectively of an incompetent mitral valve 13 such as that shown in Fig. 1. The free edge 21 of posterior valve leaflet 14 is unable to close completely against the free edge 22 of anterior leaflet 15 due to the torn cordae tendinae as depicted in Fig. 1. A similar leaflet condition may occur due to dilated ventricular architecture, i.e. dilated cardiomyopathy, which is also characteristic of congestive heart failure.

Fig. 3A illustrates a healthy competent mitral valve 13 with valve leaflets 14 and 15 which are closed completely during systole to prevent regurgitation of blood through the valve. Fig. 3B illustrates the competent mitral valve shown in Fig. 2A in an opened condition during diastole to allow blood to flow from the left atrium to the left ventricle.

Figs. 4A and 4B illustrate the closed and opened conditions of a mitral valve 13 in which the free edge 21 of posterior valve leaflet 14 and the free edge 22 of the anterior leaflet valve 15 are secured together in a "Bow-Tie" connection by a suitable clip, such as is shown in Fig. 26. During systole, when the heart contracts, the clip holds the free edges 21 and 22 of the valve leaflets together to minimize blood regurgitation through the valve. However, during diastole, when the heart muscle relaxes and the blood pressure within the left ventricle 12 is reduced, the mitral valve 13 opens up much like a competent valve but with two openings 23 and 24 between the valve leaflets 14 and 15. The interference with blood flow through the two openings 23 and 24 of a repaired mitral valve with a Bow-Tie connection between the leaflets is minimal during diastole compared to the flow with a single opening for a competent mitral valve.

Fig. 5 illustrates a left side of a patient's heart such as is shown in Fig. 1 with an incompetent mitral valve 13 due to torn cordae tendinae 14. A valve 30 embodying features of the invention is deployed within a passageway 31 through the free ventricular heart wall 32. As is shown in more detail in Figs. 6-8, the valve 30 has a cylindrical structure 33 which is secured within the passageway 31 by elements 34 which may be barbs or hooks. Other means such as suitable adhesives may be utilized to secure the valve 30 within the passageway 31. The valve component 35 of valve 30 is a duck billed valve component formed of suitable polymeric material which allow the passage of instruments for deployment or treatment but prevent or at least minimize loss of blood through the heart wall, particularly during systole. The duck-billed valve component 35 extends toward the distal end of the valve 30 to prevent blood flow from the heart chamber. The cylindrical structure 33 may be in an open-walled form similar to a stent and is preferably expandable to facilitate its deployment within the passageway 31. However, the cylindrical structure 33 may have any suitable structure or be formed of any suitable material which supports the valve component 35. The securing elements 34 may be forced into the surrounding tissue of the heart wall by means of a dumbbell shaped inflatable balloon (not shown).

Figs. 9-26 depict a grasping device 40 which embodies features of the invention and the use of the device to secure the valve leaflets in a Bow-Tie connection. The grasping device 40 has an elongated shaft 41, a plurality of grasping members or jaws 42 on the distal portion of the shaft and finger operated handles 43 and 44 which operate the jaws 42 through pull wires 45 and 46. The grasping members or jaws 42 are pivotally mounted at the pivot point 47 on the distal end of shaft 41. While only two jaws 42 are shown, three or more jaws may be employed. The elongated shaft 41 of grasping device 40 has an inner lumen 48 extending therein to allow for the passage of instruments that aid or effect the deployment of a connecting member 49 to the free edges of the valve leaflets to perform a Bow-Tie connection thereof as will be described in more detail hereinafter. Fig. 21 is an enlarged elevational view in section of the distal portion of the grasping device 40 to illustrate the connecting member 49, which is a leaflet clip, and the pusher bar 50 which pushes the clip through the inner lumen 48 of the grasping device. As shown in more detail in Figs. 22-24, tapered grooves 51 and 52 are provided in the jaws 42 so that, as the clip 49 is pushed toward the distal ends of the jaws 42, the open distal ends of the clip slide along the tapering grooves and are closed against free edges 21 and 22 of the leaflets 14 and 15 grasped by the jaws. The deployed leaflet clip 49 partially closed against the free leaflet edges 21 and 22 in a Bow-Tie connection is shown in Fig. 17 and 18. The inner lumen 48 continues through the jaws 42 to a port 51 to allow passage of other instruments such as the distal portion of the

balloon catheter 53 which stabilizes and positions the valve leaflets 14 and 15 in the grasping location as shown in Fig. 14.

The use of the grasping device 40 to make a Bow-Tie connection of the free edges 21 and 22 of the mitral valve 13 is illustrated in Figs. 9-18. After the one-way valve 30 is properly secured within the passageway 31 through the ventricular wall 32, a guide wire 54 is advanced through the valve 30 into the left ventricle 12 and further advanced through the mitral valve 13 into the left atrium 11 as shown in Fig. 10. A grasping device 40 is mounted on the proximal end of the guide wire 54 which extends out of the patient and is slidably advanced over the guide wire through the valve 30, and into the left atrium through the mitral valve 13. The guide wire 54 at that point is slidably disposed within the inner lumen 48 of the grasping device 40. A balloon catheter 53 may then be advanced over the guide wire 54 through the inner lumen 48 of the grasping device 40 until the inflatable balloon 55 on the distal portion of catheter 53 is disposed in the left atrium 11. The balloon 55 is inflated by injecting inflation fluid through an inner lumen (not shown) in the shaft of the balloon catheter 53 by means of the syringe 56 as shown in Fig. 13. If the shaft of the balloon catheter 53 is stiff enough, the guide wire 54 may be withdrawn prior to insertion of the balloon catheter 53 and the advancement thereof through the inner lumen 48 of grasping device 40 by itself.

After the balloon 55 is inflated within the left atrium 11, the balloon catheter 53 is pulled proximally to press the inflated balloon 55 against the atrial side of the mitral valve leaflets 14 and 15 to urge the leaflets into grasping location as shown in Fig. 14. The jaws 42 of the grasping device 40 may then be closed on the valve leaflets 14 and 15 as shown in Fig 15. As previously described, the leaflet clip 49 may then be advanced through the inner lumen 48 by pusher bar 50 to close the open ends of clip 49 against and through the grasped free edges 21 and 22 of valve leaflets 14 and 15 respectively, as shown in Figs. 17 and 18. After the clip 49 has been deployed to form the Bow-Tie connection, the grasping device 40 and any other devices that may be present are withdrawn from the patient's heart through the ventricular wall valve 30. The duck-billed valve component 35 closes down after removal of the various instruments and prevents loss of blood from the left ventricle. If desired, the valve 30 may be left in place or it may be removed and the proximal opening of the ventricular passageway sutured or otherwise closed or sealed.

In Fig. 26A a clip 49 is shown with a strand 57 secured to the closed proximal end. An alternate embodiment is depicted in Fig. 26B in which the closed proximal end of the clip 49 is provided with an eyelet 58. One end of the strand 57 is tied to the eyelet. A variety of clip structures may be employed to connect the free edge of the valve leaflets.

An embodiment is shown in Fig. 27 wherein an elongated strand 57 formed of relatively non-compliant material, such as PTFE, Nylon, polyethylene terephthalate, has its distal end secured to the closed proximal end of leaflet clip 49. The strand 57, if formed of PTFE, should have a transverse dimension of about 1 to about 3 mm. After deployment of the clip 49 to connect the free edges 21 and 22 of the leaflets 14 and 15 in a Bow-Tie connection, the proximal end of the strand 57 is pulled taut to position the leaflets 14 and 15 in a position to ensure proper closure during systole and then the proximal end of the strand 57 is secured to the free ventricular wall 32, preferably to the exterior thereof, such as shown suturing with a pledget 59 while maintaining the strand in a taut condition. This embodiment is particularly suitable in those instances wherein cordae tendinae connected to the valve leaflet are torn. The strand 57 acts as an artificial cordae tendinae to the leaflet. However, care must be exercised when securing the proximal end of the strand 57 is secured to the heart wall 32 so that the valve leaflets are in a natural position in order to prevent or reduce regurgitation through the mitral valve 13.

The hearts of many CHF patients exhibit intraventricular conduction delay with resulting disturbance of the synchronous right and/or left ventricular contractility. As previously mentioned, a large population of the CHF patients are not suitable candidates for or fail percutaneous delivery of pacing leads to provide relief from CHF. In these instances, it has been found that a pacing lead secured to the exterior wall defining in part the heart chamber exhibiting the conduction delay can better control the contraction of the heart and thereby improve the chamber's ejection.

As shown in Fig. 28, the pacing lead 60 can be deployed within the patient's chest cavity by minimally invasive techniques through a trocar 61 located in the intercostal space between the patient's ribs. The placement of the pacing lead 60 can be observed by an endoscopic video 62 extending through a second trocar (not shown) in a second intercostal space. Instruments to facilitate the implantation of the helically shaped penetrating electrode 63 of the pacing lead 60 can be passed through the trocar 61 and the electrode secured within the heart wall 32 by minimally invasive techniques. The pacing lead 60 has its proximal end configured to be electrically connected to a pacing power source 64 which is preferably disposed at a subcutaneous location. The pulsed output of the power source 64 may be controlled in a conventional manner to provide the desired contractions to the heart wall to which the pacing lead is secured.

Figs. 29 to 31 illustrate a minimally invasive embodiment having features of the invention directed to implanting a pacing lead in a patient's heart wall. The delivery and implanting device 70 of this embodiment includes a tubular delivery member 71 having a proximal end 72 with a port 73, an enlarged distal end 74 with a port 75 and inner lumen 76

extending within the tubular member from the proximal port 73 to the distal port 75. The distal end 74 of the tubular member 71 is enlarged to receive a longitudinally expansive member such as inflatable balloon 77. The balloon 77 is provided with an elongated shaft 78 having an inner inflation lumen (not shown) which allows inflation fluid to be introduced into the interior of the balloon to inflate the balloon. The distal end 74 of tubular member 71 is provided with a securing pod or ring 79 to releasably secure the distal end to the exposed surface of the free ventricular wall 32. The interior chamber 80 of the pod 79 is connected in fluid communication with the vacuum tube 81 which is in turn configured to be connected in fluid communication with a vacuum source (not shown). The pacing lead 82 has a collar 83 secured about a distal portion thereof which is configured to be engaged by the balloon 77 when the latter is inflated. The enlarged end 74 of the tubular delivery member 71 prevents complete radial expansion of the balloon 77 upon inflation and as a result the balloon expands longitudinally. The longitudinal expansion of balloon 77 against the collar 83 connected to the pacing lead 82 drives the penetrating electrode 84 on the pacing lead against the exposed ventricular wall 32 so that the penetrating electrode 84 penetrates into and is secured within the ventricular wall 32 by the barbs 85. The enlarged distal end 74 should be about 5 to about 15 mm in diameter and about 5 to about 40 mm in length. Other sizes may be suitable. The tubular member 71 may have a flexible section 86 to facilitate articulation of the distal extremity of the tubular member 71 to aid in the placement of the pod 79 to the exterior of the heart wall 32 and provide a sound seal for the application of a vacuum. The vacuum pod 79 is configured to pass through a trocar provided in an intercostal space between the patient's ribs.

The pacing lead 82 shown in Figs. 29-32 is installed by first making a small opening in the patient's chest and deploying a first trocar 87 such as shown in Fig. 32 having an inner lumen within the small opening. Commercially available trocars include trocars from U.S. Surgical and others. A second similar trocar 88 to place a variety of instruments within the patient's chest cavity for the procedure and a third trocar 89 is installed in a similar manner for a thoroscope which allows the operating surgeon to view the region in which the pacing lead is to be installed. Other trocars may also be installed for other purposes. A suitable arrangement of trocars 87, 88, 89 for such procedures is shown in Fig. 32.

To install the pacing lead the lower left lobe of the patient's lung, which is deflated, is moved out of the way to expose the patient's heart. Part of the pericardium on the free wall 32 defining in part the patient's left ventricle is removed to expose a desired region of the epicardial surface in which the pacing lead 81 is to be secured. The pacing lead delivery tube 71 is introduced to the patient's chest cavity through the first trocar and advanced within the chest cavity toward the exposed epicardial surface. The distal end facing of the vacuum pod 79 on the

expanded distal end 74 of the delivery tube 71 is pressed against the exposed epicardial surface of the ventricular wall 32 and a vacuum is developed within the inner chamber 80 of the pod 79 to hold the distal end of the tubular member 71 against the epicardial surface as shown in Fig. 30. Inflation fluid is introduced into the interior of the balloon 77 through the inflation lumen in tube 78 as shown by the arrows. The expanded distal end 74 of the delivery tube 71 limits the radial expansion of the balloon 77, so that the balloon expands longitudinally in the distal direction as shown in Fig. 31. The longitudinal expansion causes the distal end of the balloon to expand against the collar 83 secured to the distal portion of the pacing lead 81.

Balloon pressure on the collar 83 drives the pacing lead 82 toward the epicardial location and this results in the penetration of electrode 84 on the distal end of the pacing lead into the ventricular wall 32. The barbs 85 on the penetrating electrode 84 secure the electrode within the heart wall and resist withdrawal of the electrode from the heart wall 32. Electrical pulses from a suitable electrical power source are applied to the proximal end of the pacer lead. The electrical pulses are transmitted through the pacing lead conductor to the penetrating electrode 83 secured within the heart wall 32. The pulses are emitted from the secured electrode 84 into the tissue of the heart wall 32 to pace the patient's left ventricle. The pacing is controlled in order to increase the volume of blood pumped out of the heart chamber.

An alternative device 90 is shown in Figs. 33 and 34 which has an elongated tubular shaft 91 with a proximal end 92, a distal end 93, and a semispherical shaped housing 94 on the distal end with a securing pod 95 on the distal end 93. The securing pod 95 has an annular vacuum chamber 96 around the lower edge of the semi-spherical housing 94 which is in fluid communication with the inner lumen 97 of tubular member 98. The proximal end (not shown) of the tubular member 98 is configured to be connected in fluid communication with a vacuum source (not shown). An inner lumen 99 extends through the tubular shaft 91 and slidably receives the catheter 100 having an inflatable balloon 101 on the distal end thereof. A pacing lead 102 extends along, but exterior to, the tubular shaft 91 and has a distal end with a balloon support platform 103 and a tissue penetrating electrode 104 extending away from the platform.

A distal portion 105 of the tubular shaft 91 is provided with some degree of flexibility in order to ensure that the spherical housing 94 is in a proper orientation to be pressed against and releasably secured to the exposed epicardial surface. With the securing pod 95 secured against the epicardial surface of wall 32, the balloon 101 is inflated to drive the supporting platform 103 and the connected penetrating electrode 104 toward the epicardial surface. The electrode 104 is driven into the wall 32 of the patient's left ventricle and the barbs 106 thereon secure the electrode within the wall tissue to resist withdrawal of the electrode from its deployed position. Electrical pulses from a suitable power source may then be applied to the tissue within the heart

wall to pace the contraction thereof as discussed above to increase the output of blood from the heart chamber.

The balloon 101 is releasably secured to the support platform 103 so that when the electrode 104 is driven into the heart wall 32, the balloon 101 can be deflated and the vacuum within the vacuum chamber of the semi-spherical housing may be released and the assembly withdrawn from the patient through the trocar through which it was delivered. The proximal end of the pacing lead may then be directed to the power source and connected thereto. The shaft 91 is preferably shapeable in order to be able to place the pacing lead at the desired location on the exposed epicardial surface. The shaft 91 may be formed of stainless steel, or other metallic or other materials which allow the shaft to be manually shaped by the physician prior to insertion into the patient's chest cavity.

The tissue penetrating electrodes 83 and 104 described in the aforesaid embodiments generally have an arrow shape with a pointed distal tip to facilitate tissue penetration and two outwardly flaring barbs 85 and 106 which resist electrode withdrawal once the electrode is in place. Alternate electrode construction includes a fish-hook shaped electrode such as shown in Fig. 34 with a pointed distal tip and a single outwardly flaring barb. Similar electrode constructions are suitable including those having three or more outwardly flaring barbs.

Another alternative embodiment is shown in Figs. 35-37, which is a device 120 having an elongated tube 121 with a pair of grasping tongs 122 on the distal end 123 of the tube with a mechanism (not shown) configured to secure the tongs 121 to a pacing lead housing 124. The device 120 of this embodiment has a housing 125 on the proximal end 126 with a rotating lead holder 127 which when rotated rotates the pair of grasping tongs 122 as shown in Figs. 37 and 38. A release button 128 is provided on the housing 125 to disengage the grasping tongs 122 from the pacing lead housing 124. The rotation of the tongs 122 causes the rotation of the pacing lead housing 124 and the helical electrode 126 to screw into the heart wall 32. A similar device will soon be offered by Medtronic as an epicardial lead implant tool (Model No.10626) which is designed to be used with a Model 5071 pacing lead.

Usually, an additional (e.g., conventional) pacing lead is installed in the patient's right ventricle for complete resynchronization of the heart chambers. The additional lead is preferably connected to the same power source as the first described pacing lead which may be located in the infraclavicular pocket in a conventional manner.

#### EXAMPLE

Twenty patients were selected (12 men, 8 women) for thoroscopically direct left ventricular lead placement. The patients had New York Heart Association Class III or IV



congestive heart failure with a mean ejection fraction of  $20\% \pm 8\%$ . All of the patients had previously undergone transvenous right-ventricular lead placement and subcutaneous implantation of a dual or triple chamber pacemaker but had failed transvenous left-ventricular lead placement due to suboptimal coronary vein anatomy. Surgical entry into the left chest was carried out through a 2 cm incision in the mid axillary line at the sixth intercostal space, following collapse of the left lung. A 15 mm thoracoport (trocar 87 in Fig. 32) from U.S. Surgical was inserted with the tip of the trocar pointing to the left minimize contact with the heart. A 5 mm rigid port (trocar 88 in Fig. 32) was inserted inferolateral to the left nipple of the patient in the sixth intercostal space to allow insertion of a grasper such as the U.S. Surgical Endograsper. Another 5 mm rigid port (trocar 89 in Fig. 32) was inserted in the fourth intercostal space at the anterior axillary line for a scope and camera. A portion of the pericardium was removed to provide an exposed epicardial region by a grasper from within trocar 88 for implantation of the helical electrode of the pacing lead. Screw in epicardiac leads (Medtronic 5071 and Guidant 4047) were inserted through the 15 mm trocar or rigid port under video control by a scope within the trocar 89. The leads were inserted into the epicardium by applying gentle pressure and three clock-wise full rotations of the pacing lead holder (shown schematically in Figs. 34-36). If pacing voltage thresholds were unacceptably high the pacing lead would be twisted one-quarter turn and then retested. Acceptable pacing lead placement is defined as 100% pacing at 2.5 volts or less. The video assisted left-ventricular lead placement was successful in nineteen of the twenty patients. The one failure required an open thorocotomy.

While particular forms of the invention have been illustrated and described, it will be apparent that various modifications can be made without departing from the spirit and scope of the invention. For example, the vacuum actuated securing pod to secure the distal end of a delivery tube may be replaced in whole or part by one or more hooks or tissue grasping components disposed about the distal end of the delivery device to releasably secure the distal end to the epicardial surface during electrode placement. To the extent not otherwise described, the various components of the devices described herein may be formed of conventional materials and have conventional structures. Accordingly, it is not intended that the invention be limited to the specific embodiments illustrated. It is therefore intended that this invention be defined by the scope of the appended claims as broadly as the prior art will permit. Moreover, those skilled in the art will recognize that features shown in one embodiment may be utilized in other embodiments. Terms such as "element", "member", "device", "section", "portion", "component", "steps" and words of similar import when used herein shall not be construed as invoking the provisions of 35 U.S.C. §112(6) unless the following claims expressly use the terms "means" or

“step” followed by a particular function without specific structure or action. All patents and patent applications referred to above are hereby incorporated by reference in their entirety.

**WHAT IS CLAIMED IS**

1. A minimally invasive method of treating a patient's heart having mitral valve regurgitation from a left ventricle, comprising:

- a. forming a small passageway in the patient's left ventricular wall defining an part the patient's left ventricle;
- b. seating a valve into the passageway formed in the left ventricular wall;
- c. advancing a grasping device through the valve into the left ventricle;
- d. advancing an valve leaflet stabilizer member through the valve through the left ventricle through the mitral valve into a left atrium distal to the mitral valve;
- e. expanding the stabilizer member within the left atrium and engaging leaflets of the mitral valve and guiding the leaflets to a grasping location;
- f. grasping the leaflets in the grasping location with the grasping device; and
- g. securing together free edges of the grasped leaflets with at least one connecting member.

2. The method of claim 1 wherein the seated valve allows for passage of an instrument into and out of the left ventricle and minimizes blood flow from the left ventricle.

3. The method of claim 1 wherein one end of an artificial cordae tendinae strand is secured to the connecting member and a second end of the strand is secured to the ventricular wall to hold the mitral valve in a desired position.

4. The method of claim 3 wherein the strand is secured to the exterior of the ventricular wall.

5. The method of claim 4 wherein the strand passes through the seated valve in the ventricular wall.

6. The method of claim 3 wherein the strand is non-compliant.

7. The method of claim 5 wherein the strand is formed of a non-compliant material selected from the group consisting of nylon, polyethylene terephthalate and polytetrafluoroethylene.

8. The method of claim 1 wherein the grasping device has an inner lumen and the valve leaflet stabilizing member is configured to pass through the inner lumen of the grasping device when the stabilizing member is advanced into the patient's heart.

9. The method of claim 8 wherein the grasping device has opposed grasping jaws with inner grooves which taper distally to smaller dimensions to close a leaflet connecting member when the connecting member is distally advanced therein.

10. A minimally invasive method of treating a patient's heart which has a left ventricle that provides insufficient output, comprising:

- a. exposing an exterior region of the patient's heart wall which defines in part the left ventricle;
- b. ~~advancing a pacing lead with a penetrating electrode~~ through a small opening in the patient's chest cavity to the exposed region of the patient's heart wall;
- c. securing the pacing lead to the exposed region of the patient's heart wall with the penetrating electrode within the heart wall; and
- d. delivering electrical pulses to the penetrating electrode of the pacing lead to control the contraction of the heart wall to which the pacing lead is secured.

11. The method of claim 10 wherein a trocar is disposed in the small opening in the patient's chest to gain access to the patient's chest cavity.

12. The method of claim 10 wherein the electrical pulses have a frequency, duration, current and voltage sufficient to control the contraction of the patient's left ventricle to increase the output thereof.

13. The method of claim 10 wherein a second pacing lead is disposed in the right ventricle of the patient's heart and electrical pulses are emitted from an electrode on a distal portion of the second pacing lead having a frequency, duration, current and voltage sufficient to control the contraction of the right ventricle to increase the output thereof.

14. A method of treating a patient's heart with congestive heart failure due at least in part to regurgitation through a mitral valve and ventricular conduction delay with resulting disturbance of the synchronous ventricular contractility, comprising

~~a. forming a small passageway in the patient's left ventricular wall defining in part the patient's left ventricle.~~

~~b. seating a valve into the passageway formed in the left ventricular wall.~~

- c. advancing a grasping device through the valve into the left ventricle;
- d. advancing an expandable member through the valve, through the left ventricle, through the mitral valve into a left atrium distal to the mitral valve;
- e. expanding the expandable member within the left atrium and engaging leaflets of the mitral valve and guiding the leaflets to a grasping location;
- f. grasping the leaflets in the grasping location with the grasping device; and
- g. securing together free edges of the leaflets grasped with one or more connecting members;
- h. exposing an exterior region of the patient's heart wall which defines in part the left ventricle;

- i. ~~advancing a pacing lead with a penetrating electrode~~ through the patient's chest cavity to an exposed region of the patient's heart wall;
- j. securing the pacing lead to the exposed region of the patient's heart wall with the penetrating electrode within the heart wall; and
- k. delivering electrical pulses to the penetrating electrode of the pacing lead to control the contraction of the heart wall to which the pacing lead is secured.

15. A minimally invasive system for treating a patient's heart having heart valve regurgitation, comprising:

- a. a valve configured to be secured within a passageway formed through the patient's heart wall to provide instrument passageway into a chamber of the patient's heart defined in part by the heart wall through which the passageway is formed;
- b. a tissue grasping device configured to extend through the valve secured within the passageway into the chamber of the patient's heart and having at least two grasping members configured to grasp valve leaflets; and
- c. a tissue connecting member to connect free edges of valve leaflets.

16. The minimally invasive system of claim 15 wherein the grasping jaws of the grasping device are configured to grasp the valve leaflets with free edges disposed together to facilitate securing the free edges together with the connecting member.

17. The minimally invasive system of claim 15 including a stabilizing member for engaging valve leaflets and holding the leaflets in a grasping location.

18. The minimally invasive system of claim 17 wherein the stabilizing member is a balloon catheter.

19. The minimally invasive system of claim 18 wherein the balloon catheter has an inflatable balloon on a distal portion thereof.

20. The minimally invasive system of claim 19 wherein the balloon is formed of compliant or semi-compliant polymeric materials.

21. A minimally invasive system for treating a patient's heart having a chamber providing insufficient output by ~~securing a penetrating electrode of a pacing lead~~ within an exposed region of a patient's free ventricular wall defining in part the patient's heart chamber providing insufficient output, comprising:

- a. an elongated delivery tube having a proximal end, a distal end configured to pass through a small opening in the patient's chest, an inner lumen extending through the delivery tube to the distal end and configured to slidably receive a pacing lead.
- b. a securing pod on the distal end of the delivery tube to releasably secure the distal end of the delivery tube to the exposed region of the patient's heart wall; and

c. a driving member associated with the delivery tube and configured to engage the pacing lead and drive the penetrating electrode of the pacing lead into the exposed wall of the patient's heart to secure the penetrating electrode within the heart wall.

22. The minimally invasive system of claim 21 wherein the delivery tube has an expanded distal end.

23. The minimally invasive system of claim 22 wherein the driving member is an inflatable balloon which is disposed within the expanded distal end of the delivery tube.

24. The minimally invasive system of claim 23 wherein the balloon is longitudinally expandable.

25. A minimally invasive system for treating a patient's heart having a chamber providing insufficient output, comprising:

a. a valve configured to be secured within a passageway formed through the patient's heart wall to provide an instrument passageway into a chamber of the patient's heart defined in part by the heart wall through which the passageway is formed;

b. a tissue grasping device configured to extend through the valve into the chamber of the patient heart and to grasp free edges of valve leaflets;

c. a tissue securing assembly advanceable through the valve to secure one or more connecting members to at least one free edge of a valve leaflet;

d. ~~a pacing lead configured to be advanced~~ into the patient's chest cavity through a small opening in the patient's chest and to be secured to an exterior region of the patient's heart; and

e. an electrical pulse transmitting member having one end secured to the penetrating electrode of the pacing lead and another end configured to be connected to a source of electrical pulses.

26. A system for treating a patient with congestive heart failure including a regurgitating heart valve, comprising:

a. a connecting member for securing together free edges of valve leaflets of the patient's regurgitating heart valve; and

b. at least one strand having one end secured to the connecting member and one end ~~configured to be secured to a heart wall~~

27. The system of claim 26 wherein the strand is formed of a non-compliant polymeric material.

28. The system of claim 27 wherein the polymeric strand is formed of polytetrafluoroethylene and has transverse dimensions of about 1 to about 3 mm.

29. A minimally invasive system for ~~installing a pacing lead to an~~ exposed region of a free wall of a patient's heart, comprising:

- a. a delivery tube having a proximal end, a port in the proximal end, a distal end, a port in the distal end, an inner lumen extending from the proximal end to the distal end and in fluid communication with the ports therein and a securing pod on the distal end to releasably secure the distal end of the delivery tube to the exterior region of the patient's free heart wall;
- b. a pacing lead slidably disposed within the inner lumen of the delivery tube with a penetrating electrode on a distal portion of the pacing lead which is securable within the patient's heart wall of the exposed region and a collar on the distal portion of the lead proximal to the penetrating electrode;
- c. a driving member on the distal end of the delivery tube configured to engage the collar on the distal portion of the lead and drive the lead distally and drive the electrode of the lead into the heart wall of the exposed region of the patient's heart.

30. The system of claim 29 wherein the driving member is an expandable member at the distal end of the delivery tube configured for distal expansion to engage the collar on the distal portion of the lead to drive the penetrating electrode into the exposed region of the heart wall.

31. The system of claim 29 wherein the delivery tube has a distal portion with larger transverse dimensions than portions of the delivery tube proximal to the distal portion.

32. The system of claim 31 wherein the internal dimension of the distal end of the delivery tube ranges from about 5 to about 15 mm.

33. The system of claim 31 wherein the distal portion of the delivery tube having enlarged transverse dimensions extends a length of about 5 to about 40 mm.

34. The system of claim 29 wherein the securing pod has an inner chamber configured to be connected in fluid communication with a vacuum source.

35. The system of claim 34 wherein the securing pod extends about the distal end of the delivery tube.

36. A method of treating a patient having CHF, comprising:

- a. ~~providing a pacing lead having a pulse emitting~~ electrode on the distal end thereof;
- b. advancing the pacing lead through a trocar in the patient's chest having a maximum transverse dimension not more than 20 mm in transverse dimension;
- c. securing the pulse emitting electrode on the distal end of the pacing lead within a free wall of the patient's heart defining in part the patient's left ventricle; and
- d. emitting electrical pulses from the electrode to pace the contractions of the patient's left ventricle to increase the blood flow out of the left ventricle.

37. A minimally invasive system for treating a patient's heart having heart valve regurgitation, comprising:

- a. ~~a valve means secured~~ within a passageway formed through the patient's heart wall to provide instrument passageway into a chamber of the patient's heart defined in part by the heart wall through which the passageway is formed;
- b. tissue grasping means configured to extend through the valve secured within the passageway into the chamber of the patient's heart and to grasp valve leaflets; and
- c. means to connect free edges of valve leaflets.

38. A minimally invasive system for treating a patient's heart having a chamber providing insufficient output by securing ~~a penetrating electrode of a pacing lead~~ within an exposed region of a patient's free ventricular wall defining in part the patient's heart chamber providing insufficient output, comprising:

- a. an elongated tubular delivery means having a proximal end, a distal end configured to pass through a small opening in the patient's chest, an inner lumen extending through the delivery tube to the distal end and configured to slidably receive a pacing lead;
- b. means on the distal end of the delivery tube to releasably secure the distal end of the delivery tube to the exposed region of the patient's heart wall; and
- c. means associated with the delivery tube to engage the pacing lead and drive the penetrating electrode of the pacing lead into the exposed wall of the patient's heart to secure the penetrating electrode within the heart wall.

39. A minimally invasive system for treating a patient having CHF, comprising:

- a. valve means for accessing a CHF patient's left ventricle through a passageway in the free ventricular wall defining in part the patient's left ventricle;
- b. means for securing together free edges of the patient's mitral valve in a "Bow-Tie" configuration from within the patient's left ventricle; and

c. ~~pacing means having a penetrating electrode~~ secured within a region of the CHF patient's free heart wall defining in part the patient's left ventricle and a proximal end configured to be electrically connected to an electrical power source to the patient's free wall through the penetrating electrode suitable to pace the patient's left ventricle.

40. A minimally invasive method for treating a patient having CHF, comprising:

- a. accessing a CHF patient's left ventricle through a valved passageway in the free ventricular wall defining in part the patient's left ventricle;
- b. securing together free edges of the patient's mitral valve in a "Bow-Tie" configuration from within the patient's left ventricle by instruments passing through the valved passageway in the free ventricular wall;



c. securing an electrode of a pacing lead within a region of the CHF patient's free heart wall defining in part the patient's left ventricle; and

d. delivering electrical pulses from an electrical power source to the pacing lead to deliver electrical pulses to the patient's free wall suitable to pace the patient's left ventricle.

41. A minimally invasive grasping device to secure tissue together with a connecting member comprising:

a. at least a pair of opposed jaws configured to grasp tissue;

b. a pair of operative handles, with each handle being operatively connected to one of the jaws; and

c. an elongated shaft having an inner lumen configured to slidably receive a connecting member.

42. The grasping device of claim 41 wherein at least one of the jaws has a tapering groove to at least partially close the connecting member when the connecting member is advanced distally through the inner lumen into the opposing jaws.

43. The system of claim 41 wherein the connecting member has an open distal end and a closed proximal end.

44. The system of claim 43 wherein an artificial cordae tendinae strand is secured to the closed proximal end of the connecting member.

45. The system of claim 44 wherein the artificial cordae tendinae strand is configured to extend between connected one or more valve leaflets and a heart wall.

46. The system of claim 44 wherein the artificial cordae tendinae strand is formed of non-compliant polymeric material.

47. A pacing lead comprising an elongated electrical pulse transmitting member having a proximal end configured to be connected in an electrical conducting relationship with a source of electrical pulses, and a distal end having a tissue penetrating electrode with one or more barbs to resist electrode removal from tissue in which the electrode is implanted.

48. The pacing lead of claim 47 wherein the tissue penetrating electrode has an arrow shape.

49. The pacing lead of claim 47 wherein the tissue penetrating electrode has a fish-hook shape.

50. A minimally invasive method for treating a patient having CHF, comprising the steps of:

a. accessing a CHF patient's left ventricle through a valved passageway in the free ventricular wall defining in part the patient's left ventricle;

- b. securing together free edges of the patient's mitral valve in a "Bow-Tie" configuration from within the patient's left ventricle by instruments passing through the valved passageway in the free ventricular wall;
- c. ~~securing an electrode of a pacing lead within a region of the CHF patient's free heart wall defining in part the patient's left ventricle; and~~
- d. delivering electrical pulses from an electrical power source to the pacing lead to deliver electrical pulses to the patient's free wall suitable to pace the patient's left ventricle.

51. A minimally invasive method of treating a patient's heart having mitral valve regurgitation from a left ventricle, comprising the steps of:

- a. forming a small passageway in the patient's left ventricular wall defining in part the patient's left ventricle;
- b. seating a valve into the passageway formed in the left ventricular wall;
- c. advancing a grasping device through the valve into the left ventricle;
- d. advancing a valve leaflet stabilizer member through the valve, through the left ventricle, through the mitral valve into a left atrium distal to the mitral valve;
- e. expanding the stabilizer member within the left atrium and engaging leaflets of the mitral valve and guiding the leaflets to a grasping location;
- f. grasping the leaflets in the grasping location with the grasping device; and
- g. securing together free edges of the grasped leaflets with at least one connecting member.

52. A minimally invasive method of treating a patient's heart which has a left ventricle that provides insufficient output, comprising the steps of:

- a. exposing an exterior region of the patient's heart wall which defines in part the left ventricle;
- b. advancing a pacing lead with a penetrating electrode through a small opening in the patient's chest cavity to the exposed region of the patient's heart wall;
- c. ~~securing the pacing lead to the exposed region of the patient's heart wall with the penetrating electrode within the heart wall; and~~
- d. delivering electrical pulses to the penetrating electrode of the pacing lead to control the contraction of the heart wall to which the pacing lead is secured.

53. A method for treating a patient having a regurgitating heart valve, comprising:

- a. securing together free edges of the patient's regurgitating heart valve in a "Bow-Tie" configuration from within the patient's heart; and
- b. ~~securing one end of an artificial cordae tendinae to the free edges of the heart valve~~ and another end to a heart wall which defines in part a heart chamber.

54. The method of claim 53 including accessing the patient's heart chamber in fluid communication with the regurgitating heart valve and securing the free edges of the heart valve together from within the heart chamber.

1/19




FIG. 1

2/19




FIG. 2A




FIG. 2B




FIG. 3A




FIG. 3B




FIG. 4A




FIG. 4B

3/19




FIG. 5




FIG. 7




FIG. 6




FIG. 8

4/19




FIG. 9




FIG. 10

5/19




FIG. 11




FIG. 12



6/19




FIG. 13




FIG. 14

7/19




FIG. 15




FIG. 16

8/19




FIG. 17






FIG. 18

9/19



10/19




FIG. 21




FIG. 24




FIG. 23




FIG. 22




FIG. 25

11/19




FIG. 26A




FIG. 26B




FIG. 27

12/19





FIG. 28

13/19





14/19




FIG. 30

15/19




FIG. 31

16/19




FIG. 32

17/19




FIG. 33




FIG. 35




FIG. 34



19/19




FIG. 37




FIG. 38